The University of Kentucky (UK) is a major public research university located in Lexington, Kentucky. Founded in 1865 as the Agricultural and Mechanical College of Kentucky, the university has grown to become the state's flagship research institution with over 30,000 students. UK is home to one of the nation's original NIH-funded Alzheimer's Disease Research Centers through its Sanders-Brown Center on Aging, established in 1972, making it one of the oldest and most experienced centers for neurodegenerative disease research in the United States[1].
The university's research programs have made significant contributions to understanding Alzheimer's disease, Parkinson's disease, and related conditions, with particular focus on the unique characteristics of disease in Appalachian and rural populations.
| Attribute | Details |
|---|---|
| Full Name | University of Kentucky |
| Location | Lexington, Kentucky, USA |
| Type | Public Research University |
| Founded | 1865 |
| Enrollment | ~30,000 students |
| Colleges | 18 colleges and professional schools |
| Website | uky.edu |
| Research Focus | Alzheimer's Disease, Parkinson's Disease, Aging, Rural Health |
The University of Kentucky was established in 1865 as the Agricultural and Mechanical College of Kentucky. The institution evolved into a comprehensive university throughout the 20th century, with the College of Medicine being established in 1960. The university has been designated as a Research 1 institution by the Carnegie Classification system, reflecting its extensive research portfolio.
The Sanders-Brown Center on Aging was established in 1972 with funding from the National Institute on Aging, making it one of the original Alzheimer's Disease Research Centers in the United States. This center has provided over 50 years of continuous research into aging and neurodegenerative diseases, contributing to major advances in understanding Alzheimer's disease progression and developing diagnostic criteria[2].
In 2024, UK received additional NIH funding to expand its Alzheimer's Disease Research Center, strengthening its capacity for clinical research, neuroimaging, and biomarker studies[3].
The Sanders-Brown Center on Aging is UK's flagship center for aging and neurodegeneration research. Founded in 1972, it is one of the oldest NIH-funded Alzheimer's Disease Research Centers in the nation.
Research Programs:
Alzheimer's Disease Research: Comprehensive clinical and basic research programs examining disease mechanisms, biomarkers, and therapeutic targets. The center maintains extensive brain bank resources for neuropathological studies[2:1].
Normal Brain Aging: Longitudinal studies of aging in cognitively normal individuals, examining factors that promote healthy brain aging versus those that contribute to cognitive decline.
Caregiver Support and Outreach: Programs supporting families and patients with neurodegenerative diseases, including education, support groups, and community outreach programs.
Education and Training: Professional training programs for healthcare providers, researchers, and students interested in aging and neurodegeneration.
The ADRC provides infrastructure for collaborative research across multiple domains:
Clinical Core: Patient recruitment and longitudinal studies tracking disease progression from preclinical to advanced stages. Studies examine cognitive, behavioral, and functional outcomes.
Neuropathology Core: Brain tissue banking and comprehensive neuropathological analysis, contributing to understanding the relationship between brain pathology and clinical symptoms[4].
Data Management Core: Research data coordination, including standardized assessments, neuroimaging data, and biospecimen tracking.
Outreach Core: Community engagement and education programs, particularly targeting the underserved Appalachian population.
Biomarker Development: UK researchers have been leaders in developing and validating biomarkers for early Alzheimer's disease detection, including cerebrospinal fluid and blood-based markers. Studies in Appalachian Kentucky populations have identified unique biomarker patterns[5].
Neuroimaging: Advanced neuroimaging research using MRI and PET to examine brain structure and function in aging and neurodegenerative diseases. Studies have characterized regional atrophy patterns and connectivity changes[6].
Genetics: Research examining genetic risk factors for Alzheimer's disease in Appalachian populations, including APOE and other susceptibility genes. Studies have identified population-specific genetic variations[7][8].
Clinical Trials: UK participates in national clinical trials for Alzheimer's disease therapeutics, testing disease-modifying agents and symptomatic treatments.
Rural and Appalachian Health: Unique research focus on neurodegenerative diseases in rural and Appalachian populations, examining health disparities and developing culturally appropriate interventions[9][10].
UK researchers study the role of neuroinflammation in neurodegenerative diseases, with particular focus on:
Research examines how vascular disease contributes to cognitive impairment and dementia:
Basic science research investigates molecular mechanisms of neurodegeneration:
Sanders-Brown Building: State-of-the-art research laboratories dedicated to neurodegeneration research, including molecular biology, biochemistry, and cell culture facilities.
UK Healthcare Neurology: Clinical care facilities including the Memory Disorders Clinic and Movement Disorders Center.
Brain Bank: Human brain tissue for research, with detailed clinical and pathological characterization.
PET Imaging Center: Molecular imaging capabilities including amyloid and tau PET.
MRI Imaging Suite: Advanced MRI including 3T scanners for structural and functional neuroimaging.
| Researcher | Position | Focus Areas |
|---|---|---|
| Dr. Peter Nelson | Neuropathology | Alzheimer's disease neuropathology, Tau biology |
| Dr. William "Bud" Grant | Neurology | Movement disorders, Parkinson's disease |
| Dr. Greg Jicha | Clinical Research | Alzheimer's disease, biomarkers |
| Larry Schmitt | Neuropsychology | Cognitive assessment, clinical trials |
| Dr. Linda Van Eldik | Neuroinflammation | Microglia, neuroimmune responses |
| Dr. Steve Estus | Genetics | APOE, lipid metabolism |
| Dr. Doug Fardo | Statistics/Genetics | Genetic epidemiology |
UK offers comprehensive training in aging and neurodegeneration:
UK participates in major research networks:
| Disease | Research Intensity | Key Programs |
|---|---|---|
| Alzheimer's Disease | Very High | Biomarkers, clinical trials, neuropathology |
| Parkinson's Disease | High | Movement disorders, neuroimaging |
| Vascular Dementia | High | Rural health disparities |
| Lewy Body Dementia | Moderate | Clinical characterization |
| ALS | Moderate | Clinical studies |
UK's Sanders-Brown Center has extensive community outreach programs:
Sanders-Brown Center on Aging. Annual research report 2024. 2024. ↩︎
Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status. Journal of Neuropathology & Experimental Neurology. 2012. ↩︎ ↩︎
UK Alzheimer's Disease Research Center. Program description and research 2024. 2024. ↩︎
Schneider JA, et al. Neuropathology of older persons without cognitive impairment. Neurology. 2012. ↩︎
Hutton D, et al. CSF biomarkers in Kentucky Appalachian Alzheimer's disease cohorts. Alzheimer's & Dementia. 2013. ↩︎
Smith CD, et al. Neuroimaging in Kentucky Appalachian Alzheimer's cohorts. NeuroImage: Clinical. 2020. ↩︎
Estus S, et al. APOE and lipid metabolism in Appalachian Alzheimer's cohorts. Neurobiology of Aging. 2018. ↩︎
Fardo DW, et al. Genetics of Alzheimer's disease in Appalachian Kentucky populations. PLoS One. 2022. ↩︎
Krich C, et al. Rural health disparities in Alzheimer's disease: Kentucky observations. Rural Remote Health. 2014. ↩︎
Abner EL, et al. Dementia epidemiology in rural Kentucky: the ACHOLIST study. Journal of Alzheimer's Disease. 2021. ↩︎
Van Eldik LJ, et al. Microglial activation in Kentucky Alzheimer's disease research. Journal of Neuroinflammation. 2020. ↩︎
Wang J, et al. Neuroinflammation in Appalachian Alzheimer's disease cohorts. Acta Neuropathologica Communications. 2023. ↩︎
Carroll SL, et al. Vascular risk factors and cognitive decline in the Kentucky appalachian region. Journal of the American Geriatrics Society. 2011. ↩︎
Matsumoto K, et al. Vascular contributions to cognitive impairment in Appalachian Kentucky. Stroke. 2022. ↩︎
Binder LI, et al. Tau biology and therapeutic targeting in Kentucky research. Journal of Neurochemistry. 2019. ↩︎
Ko H, et al. Beta-secretase activity in Kentucky Appalachian brain tissue. Journal of Alzheimer's Disease. 2019. ↩︎
Thompson J, et al. Mitochondrial dysfunction in Kentucky neurodegenerative disease studies. Journal of Bioenergetics and Biomembranes. 2021. ↩︎